Shortening Duration of Antiarrhythmic Medication for SVT in Infants

The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with SVT. Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.

Study Overview

• Status: Completed
• Conditions: Supraventricular Tachycardia
• Intervention / Treatment: Drug: Propranolol; Drug: Flecainide; Drug: Amiodarone

• Study Type: Observational
• Enrollment (Actual): 107

Contacts and Locations

Study Locations

• Finland
  • Central Finland
    • Jyväskylä, Central Finland, Finland, 40620
      • Central Finland Central Hospital
  • Kainuu
    • Kajaani, Kainuu, Finland, 87300
      • Kajaani Central Hospital
  • Kanta-Häme
    • Hämeenlinna, Kanta-Häme, Finland, 13530
      • Hämeenlinna Central Hospital
  • Keski-Pohjanmaa
    • Kokkola, Keski-Pohjanmaa, Finland, 67200
      • Kokkola Central Hopsital
  • Lapland
    • Rovaniemi, Lapland, Finland, 96101
      • Lapland Central Hospital
  • North Ostrobothnia
    • Oulu, North Ostrobothnia, Finland, 90220
      • Oulu University Hospital
  • Northern Savonia
    • Kuopio, Northern Savonia, Finland, 70029
      • Kuopio University Hospital
  • Paijat-Hame Region
    • Lahti, Paijat-Hame Region, Finland, 15850
      • Lahti Central Hospital
  • Pirkanmaa
    • Tampere, Pirkanmaa, Finland, 33520
      • Tampere University Hospital
  • Pohjanmaa
    • Vaasa, Pohjanmaa, Finland, 65130
      • Vaasa Central Hospital
  • Pohjois-Karjala
    • Joensuu, Pohjois-Karjala, Finland, 80210
      • North Karelia Central Hospital
  • Region of Kymenlaakso
    • Kotka, Region of Kymenlaakso, Finland, 48210
      • Kymenlaakso Central Hospital
  • Satakunta
    • Pori, Satakunta, Finland, 28500
      • Sakunta Central Hospital
  • South Karelia Region
    • Lappeenranta, South Karelia Region, Finland, 53130
      • South Karelia Central Hospital
  • South Ostrobothnia
    • Seinäjoki, South Ostrobothnia, Finland, 60220
      • Seinäjoki Central Hospital
  • South Savo
    • Mikkeli, South Savo, Finland, 50100
      • Mikkeli Central Hospital
  • Southwest
    • Turku, Southwest, Finland, 20521
      • Turku University Hospital
  • Uusimaa
    • Helsinki, Uusimaa, Finland, 00029
      • Helsinki University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 6 months (Child)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Infants age less than 6 months with SVT due to AVRT or AVNRT

Description

Inclusion Criteria:

• Age 6 months or less
• Documented SVT due to AVRT or AVNRT

Exclusion Criteria:

• Age > 6 months
• Ectopic atrial tachycardia
• Atrial flutter
• Atrial fibrillation
• Permanent junctional reciprocating tachycardia

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Recurrence of SVT after antiarrhythmic medication	1 year follow-up

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of participants with treatment failure	4 months of antiarrhythmic medication
Prevalence of adverse events	4 months of antiarrhythmic medication
Recurrence of SVT after one year follow-up	5 year

Collaborators and Investigators

• Sponsor: Tampere University Hospital
• Collaborators: Turku University Hospital; Helsinki University Central Hospital; Oulu University Hospital; Kuopio University Hospital
• Investigators: Principal Investigator: Tuija Poutanen, MD, Tampere University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 15, 2021
• Primary Completion (Actual): January 31, 2024
• Study Completion (Actual): January 31, 2024

Study Registration Dates

• First Submitted: April 7, 2021
• First Submitted That Met QC Criteria: April 7, 2021
• First Posted (Actual): April 8, 2021

Study Record Updates

• Last Update Posted (Actual): November 20, 2025
• Last Update Submitted That Met QC Criteria: November 17, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Tachycardia, Supraventricular
• Additional Relevant MeSH Terms: Cardiac Conduction System Disease; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Tachycardia; Pathological Conditions, Signs and Symptoms; Tachycardia, Supraventricular; Arrhythmias, Cardiac; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Amines; Piperidines; Alcohols; Phenoxypropanolamines; Propanolamines; Amino Alcohols; Propanols; Benzofurans; Amiodarone; Propranolol; Flecainide
• Other Study ID Numbers: R20113

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No